Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:administeredBy |
oral
|
| gptkbp:alternativeName |
AZD6094
volitinib |
| gptkbp:approvedBy |
gptkb:non-small_cell_lung_cancer
gptkb:China |
| gptkbp:ATCCode |
L01EX23
|
| gptkbp:CASNumber |
1313725-88-3
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:AstraZeneca
gptkb:Hutchison_MediPharma |
| gptkbp:hasMolecularFormula |
C22H17N7O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
savolitinib
|
| gptkbp:indication |
MET exon 14 skipping mutation-positive NSCLC
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
MET tyrosine kinase inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting edema fatigue increased liver enzymes |
| gptkbp:target |
gptkb:MET_receptor
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:c-Met
|
| gptkbp:bfsLayer |
6
|